keyword
MENU ▼
Read by QxMD icon Read
search

dementia pet

keyword
https://www.readbyqxmd.com/read/28097206/-18-f-av-1451-pet-in-behavioral-variant-frontotemporal-dementia-due-to-mapt-mutation
#1
W Richard Bevan Jones, Thomas E Cope, Luca Passamonti, Tim D Fryer, Young T Hong, Franklin Aigbirhio, Jillian J Kril, Shelley L Forrest, Kieren Allinson, Jonathan P Coles, P Simon Jones, Maria G Spillantini, John R Hodges, John T O'Brien, James B Rowe
The validation of tau radioligands could improve the diagnosis of frontotemporal lobar degeneration and the assessment of disease-modifying therapies. Here, we demonstrate that binding of the tau radioligand [(18)F]AV-1451 was significantly abnormal in both magnitude and distribution in a patient with familial frontotemporal dementia due to a MAPT 10 + 16C>T gene mutation, recapitulating the pattern of neuropathology seen in her father. Given the genetic diagnosis and the non-Alzheimer's pathology, these findings suggest that [(18)F]AV-1451 might be a useful biomarker in primary tauopathies...
December 2016: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/28095900/post-stroke-dementia-a-comprehensive-review
#2
REVIEW
Milija D Mijajlović, Aleksandra Pavlović, Michael Brainin, Wolf-Dieter Heiss, Terence J Quinn, Hege B Ihle-Hansen, Dirk M Hermann, Einor Ben Assayag, Edo Richard, Alexander Thiel, Efrat Kliper, Yong-Il Shin, Yun-Hee Kim, SeongHye Choi, San Jung, Yeong-Bae Lee, Osman Sinanović, Deborah A Levine, Ilana Schlesinger, Gillian Mead, Vuk Milošević, Didier Leys, Guri Hagberg, Marie Helene Ursin, Yvonne Teuschl, Semyon Prokopenko, Elena Mozheyko, Anna Bezdenezhnykh, Karl Matz, Vuk Aleksić, DafinFior Muresanu, Amos D Korczyn, Natan M Bornstein
Post-stroke dementia (PSD) or post-stroke cognitive impairment (PSCI) may affect up to one third of stroke survivors. Various definitions of PSCI and PSD have been described. We propose PSD as a label for any dementia following stroke in temporal relation. Various tools are available to screen and assess cognition, with few PSD-specific instruments. Choice will depend on purpose of assessment, with differing instruments needed for brief screening (e.g., Montreal Cognitive Assessment) or diagnostic formulation (e...
January 18, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28093088/diagnostic-impact-of-18-f-flutemetamol-pet-in-early-onset-dementia
#3
Marissa D Zwan, Femke H Bouwman, Elles Konijnenberg, Wiesje M van der Flier, Adriaan A Lammertsma, Frans R J Verhey, Pauline Aalten, Bart N M van Berckel, Philip Scheltens
BACKGROUND: Early-onset dementia patients often present with atypical clinical symptoms, hampering an accurate clinical diagnosis. The purpose of the present study was to assess the diagnostic impact of the amyloid-positron emission tomography (PET) imaging agent [(18)F]flutemetamol in early-onset dementia patients, in terms of change in (confidence in) diagnosis and patient management plan. METHODS: This prospective bi-center study included 211 patients suspected of early-onset dementia who visited a tertiary memory clinic...
January 17, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28088881/an-industry-update-the-latest-developments-in-therapeutic-delivery
#4
Iain Simpson
This Industry Update covers the period from 1 October through to 31 October 2016, and is based on information sourced from company press releases, scientific literature, patents and various news websites. The month saw several news items covering drug-delivery devices, including a new sensor to monitor and support the use of inhalers; launch in the UK of a new autoinjector for Cimzia(®), UCB's rheumatoid arthritis drug; and approval of Roche's Lucentis(®) in a prefilled syringe. Research was also published to show the value of continuous blood pressure monitoring in dementia management...
February 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28077020/relationship-between-18-f-flutemetamol-uptake-and-rbans-performance-in-non-demented-community-dwelling-older-adults
#5
Dustin B Hammers, Taylor J Atkinson, Bonnie C A Dalley, Kayla R Suhrie, Britney E Beardmore, Lance D Burrell, Kevin P Horn, Kelli M Rasmussen, Norman L Foster, Kevin Duff, John M Hoffman
OBJECTIVE: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been used extensively for clinical care and in research for patients with mild cognitive impairment and Alzheimer's disease (AD); however, relatively few studies have evaluated the relationship between RBANS performance and AD imaging biomarkers. The purpose of the current study was to evaluate the association between a relatively new amyloid positron emission tomography imaging biomarker and performance on the RBANS...
January 12, 2017: Clinical Neuropsychologist
https://www.readbyqxmd.com/read/28072381/magnetic-resonance-imaging-and-positron-emission-tomography-in-the-diagnosis-of-neurodegenerative-dementias
#6
REVIEW
A Del Sole, S Malaspina, Alberto Magenta Biasina
Neuroimaging, both with magnetic resonance imaging (MRI) and positron emission tomography (PET), has gained a pivotal role in the diagnosis of primary neurodegenerative diseases. These two techniques are used as biomarkers of both pathology and progression of Alzheimer's disease (AD) and to differentiate AD from other neurodegenerative diseases. MRI is able to identify structural changes including patterns of atrophy characterizing neurodegenerative diseases, and to distinguish these from other causes of cognitive impairment, e...
October 2016: Functional Neurology
https://www.readbyqxmd.com/read/28064175/neuroimaging-of-inflammation-in-memory-and-related-other-disorders-nimrod-study-protocol-a-deep-phenotyping-cohort-study-of-the-role-of-brain-inflammation-in-dementia-depression-and-other-neurological-illnesses
#7
W Richard Bevan-Jones, Ajenthan Surendranathan, Luca Passamonti, Patricia Vázquez Rodríguez, Robert Arnold, Elijah Mak, Li Su, Jonathan P Coles, Tim D Fryer, Young T Hong, Guy Williams, Franklin Aigbirhio, James B Rowe, John T O'Brien
INTRODUCTION: Inflammation of the central nervous system is increasingly regarded as having a role in cognitive disorders such as dementia and depression, but it is not clear how such inflammation relates to other aspects of neuropathology, structural and functional changes in the brain and symptoms (as assessed via clinical and neuropsychological assessment and MRI). This study will explore these pathophysiological mechanisms using positron emission tomography (PET) which allows in vivo imaging of inflammation, amyloid and τ deposition, together with neuropsychological profiling, MRI and peripheral biomarker analysis...
January 7, 2017: BMJ Open
https://www.readbyqxmd.com/read/28063108/validation-of-18-f-fdg-pet-single-subject-optimized-spm-procedure-with-different-pet-scanners
#8
Luca Presotto, Tommaso Ballarini, Silvia Paola Caminiti, Valentino Bettinardi, Luigi Gianolli, Daniela Perani
(18)F-fluoro-deoxy-glucose Positron Emission Tomography (FDG-PET) allows early identification of neurodegeneration in dementia. The use of an optimized method based on the SPM software package highly improves diagnostic accuracy. However, the impact of different scanners for data acquisition on the SPM results and the effects of different pools of healthy subjects on the statistical comparison have not been investigated yet. Images from 144 AD patients acquired using six different PET scanners were analysed with an optimized single-subject SPM procedure to identify the typical AD hypometabolism pattern at single subject level...
January 6, 2017: Neuroinformatics
https://www.readbyqxmd.com/read/28062720/multimodal-characterization-of-older-apoe2-carriers-reveals-selective-reduction-of-amyloid-load
#9
Michel J Grothe, Sylvia Villeneuve, Martin Dyrba, David Bartrés-Faz, Miranka Wirth
OBJECTIVE: To comprehensively assess neurobiological effects of the protective APOE2 allele in the aged brain using a cross-sectional multimodal neuroimaging approach. METHODS: Multimodal neuroimaging data were obtained from a total of 572 older individuals without dementia (cognitively normal and mild cognitive impairment) enrolled in the Alzheimer's Disease Neuroimaging Initiative and included assessments of regional amyloid load with AV45-PET, glucose metabolism with fluorodeoxyglucose-PET, and gray matter volume with structural MRI...
January 6, 2017: Neurology
https://www.readbyqxmd.com/read/28061383/increased-blood-brain-barrier-permeability-is-associated-with-dementia-and-diabetes-but-not-amyloid-pathology-or-apoe-genotype
#10
Shorena Janelidze, Joakim Hertze, Katarina Nägga, Karin Nilsson, Christer Nilsson, Malin Wennström, Danielle van Westen, Kaj Blennow, Henrik Zetterberg, Oskar Hansson
Blood-brain barrier (BBB) dysfunction might be an important component of many neurodegenerative disorders. In this study, we investigated its role in dementia using large clinical cohorts. The cerebrospinal fluid (CSF)/plasma albumin ratio (Qalb), an indicator of BBB (and blood-CSF barrier) permeability, was measured in a total of 1015 individuals. The ratio was increased in patients with Alzheimer's disease, dementia with Lewy bodies or Parkinson's disease dementia, subcortical vascular dementia, and frontotemporal dementia compared with controls...
December 5, 2016: Neurobiology of Aging
https://www.readbyqxmd.com/read/28058207/memory-loss-five-new-things
#11
Ferenc Deak, Nidhi Kapoor, Calin Prodan, Linda A Hershey
PURPOSE OF REVIEW: Memory loss can be due to a wide variety of causes. We provide new information about the biology of common genetic and acquired causes of memory loss in older adults. RECENT FINDINGS: New data are available about the genetics of Alzheimer disease (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia. Amyloid PET, FDG-PET, and MRI have improved our understanding of how mild cognitive impairment evolves to AD. Several studies have shown links between concussion and chronic traumatic encephalopathy...
December 2016: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/28024995/synergistic-interaction-between-amyloid-and-tau-predicts-the-progression%C3%A2-to-dementia
#12
Tharick A Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L Benedet, Sara Mohades, Seqian Wang, Tom Beaudry, Min Su Kang, Jean-Paul Soucy, Aurelie Labbe, Serge Gauthier, Pedro Rosa-Neto
INTRODUCTION: Recent literature proposes that amyloid-β and phosphorylated tau (p-tau) synergism accelerates biomarker abnormalities in controls. Yet, it remains to be answered whether this synergism is the driving force behind Alzheimer disease (AD) dementia. METHODS: We stratified 314 mild cognitive impairment individuals using [(18)F]florbetapir positron emission tomography amyloid-β imaging and cerebrospinal fluid p-tau. Regression and voxel-based logistic regression models with interaction terms evaluated 2-year changes in cognition and clinical status as a function of baseline biomarkers...
December 23, 2016: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/28017230/longitudinal-study-of-cognitive-and-cerebral-metabolic-changes-in-parkinson-s-disease
#13
Toru Baba, Yoshiyuki Hosokai, Yoshiyuki Nishio, Akio Kikuchi, Kazumi Hirayama, Kyoko Suzuki, Takafumi Hasegawa, Masashi Aoki, Atsushi Takeda, Etsuro Mori
OBJECTIVE: To investigate the cortical metabolic alterations that precedes longitudinal cognitive decline in Parkinson's disease (PD). METHODS: We analyzed the data of 46 PD patients who did not have dementia at baseline and completed 3-year follow-up. Based on the results of general cognitive, memory and visuospatial tests, patients were classified into cognitively normal PD (PD-CogNL), PD with mild cognitive impairment (PD-MCI), and PD dementia (PDD). The regional cerebral glucose metabolism at rest was measured using (18)F-fluorodeoxyglucose positron emission tomography...
January 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28013122/development-of-11-c-3-h-thk-5351-a-potential-novel-carbon-11-tau-imaging-pet-radioligand
#14
Vladimir Stepanov, Marie Svedberg, Zhisheng Jia, Raisa Krasikova, Laetitia Lemoine, Nobujuki Okamura, Shozo Furumoto, Nicholas Mitsios, Jan Mulder, Bengt Långström, Agneta Nordberg, Christer Halldin
INTRODUCTION: Due to the rise in the number of patients with dementia the imperative for finding new diagnostic and treatment options becomes ever more pressing. While significant progress has been made in PET imaging of Aβ aggregates both in vitro and in vivo, options for imaging tau protein aggregates selectively are still limited. Based on the work previously published by researchers from the Tohoku University, Japan, that resulted in the development of [(18)F]THK-5351, we have undertaken an effort to develop a carbon-11 version of the identical structure - [(11)C]THK-5351...
December 9, 2016: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28009725/cognitive-decline-and-dementia-in-down-syndrome
#15
Rosalyn Hithersay, Sarah Hamburg, Bernice Knight, André Strydom
PURPOSE OF REVIEW: Alzheimer's disease is most likely universal in older individuals with Down syndrome, due to having three copies of the amyloid precursor protein gene, resulting in amyloid-beta plaque deposition. Down syndrome is an important population in which to consider clinical trials of treatments to prevent or delay the development of dementia. However, assessment of subtler cognitive changes is challenging due to the presence of intellectual disability. RECENT FINDINGS: Recent research confirmed that older adults with Down syndrome often present with cognitive decline: more than 80% may experience dementia by age 65 years...
December 21, 2016: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/28008425/quantitative-pet-mri-evaluation-and-application-in-dementia
#16
Yongxia Zhou
A recently introduced integrated scanner combining simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) (PET/MRI) acquisition presents a unique set of opportunities for neuroimaging research and dementia in particular [1]. Among these, the intrinsic co-registration of the images has the potential to reduce errors in multi-modality image registration, which could lead to better quantification of longitudinal volumetric changes in neuroanatomical features that are important for assessing disease progression...
June 2016: Jacobs J Med Diagn Med Imaging
https://www.readbyqxmd.com/read/27989773/in-vivo-detection-of-microstructural-correlates-of-brain-pathology-in-preclinical-and-early-alzheimer-disease-with-magnetic-resonance-imaging
#17
Yue Zhao, Marcus E Raichle, Jie Wen, Tammie L Benzinger, Anne M Fagan, Jason Hassenstab, Andrei G Vlassenko, Jie Luo, Nigel J Cairns, Jon J Christensen, John C Morris, Dmitriy A Yablonskiy
BACKGROUND: Alzheimer disease (AD) affects at least 5 million individuals in the USA alone stimulating an intense search for disease prevention and treatment therapies as well as for diagnostic techniques allowing early identification of AD during a long pre-symptomatic period that can be used for the initiation of prevention trials of disease-modifying therapies in asymptomatic individuals. METHODS: Our approach to developing such techniques is based on the Gradient Echo Plural Contrast Imaging (GEPCI) technique that provides quantitative in vivo measurements of several brain-tissue-specific characteristics of the gradient echo MRI signal (GEPCI metrics) that depend on the integrity of brain tissue cellular structure...
December 15, 2016: NeuroImage
https://www.readbyqxmd.com/read/27987555/clinical-amyloid-imaging
#18
REVIEW
Atul Mallik, Alex Drzezga, Satoshi Minoshima
Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of Alzheimer disease (AD). Recently, amyloid PET radiotracers have been developed and approved for clinical use in the evaluation of suspected neurodegenerative disorders. In both research and clinical settings, amyloid PET imaging has provided important diagnostic and prognostic information for the management of patients with possible AD, mild cognitive impairment (MCI), and other challenging diagnostic presentations. Although the overall impact of amyloid imaging is still being evaluated, the Society of Nuclear Medicine and Molecular Imaging and Alzheimer's Association Amyloid Imaging Task Force have created appropriate use criteria for the standard clinical use of amyloid PET imaging...
January 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/27983553/down-syndrome-partial-trisomy-21-and-absence-of-alzheimer-s-disease-the-role-of-app
#19
Eric Doran, David Keator, Elizabeth Head, Michael J Phelan, Ron Kim, Minodora Totoiu, Jorge R Barrio, Gary W Small, Steven G Potkin, Ira T Lott
Overexpression of the amyloid precursor protein (APP) gene on chromosome 21 in Down syndrome (DS) has been linked to increased brain amyloid levels and early-onset Alzheimer's disease (AD). An elderly man with phenotypic DS and partial trisomy of chromosome 21 (PT21) lacked triplication of APP affording an opportunity to study the role of this gene in the pathogenesis of dementia. Multidisciplinary studies between ages 66-72 years comprised neuropsychological testing, independent neurological exams, amyloid PET imaging with 11C-Pittsburgh compound-B (PiB), plasma amyloid-β (Aβ) measurements, and a brain autopsy examination...
December 9, 2016: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/27983552/histopathology-and-florbetaben-pet-in-patients-incorrectly-diagnosed-with-alzheimer-s-disease
#20
Marwan N Sabbagh, Barbara Schäuble, Keshav Anand, Danielle Richards, Shigeo Murayama, Hiroyasu Akatsu, Masaki Takao, Christopher C Rowe, Colin L Masters, Henryk Barthel, Hermann-Josef Gertz, Oliver Peters, Natalie Rasgon, Aleksandar Jovalekic, Osama Sabri, Walter J Schulz-Schaeffer, John Seibyl
Of 57 individuals diagnosed with Alzheimer's disease (AD) in a phase III study, 13 (23%) had amyloid-β (Aβ) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aβ negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aβ in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios...
December 9, 2016: Journal of Alzheimer's Disease: JAD
keyword
keyword
68325
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"